Attention deficit hyperactivity disorder and Paranasal sinus hypersecretion
Paranasal sinus hypersecretion is found among people with Attention deficit hyperactivity disorder, especially for people who are male, 30-39 old.
The study analyzes which people have Paranasal sinus hypersecretion with Attention deficit hyperactivity disorder. It is created by eHealthMe based on reports of 6 people who have Attention deficit hyperactivity disorder from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
6 people who have Attention Deficit Hyperactivity Disorder and Paranasal Sinus Hypersecretion are studied.
What is Attention deficit hyperactivity disorder?
Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 1,461 drugs and 1,186 conditions by eHealthMe.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 703 drugs and 386 conditions by eHealthMe.
Number of Paranasal sinus hypersecretion in Attention deficit hyperactivity disorder reports submitted per year:
Gender of people who have Attention Deficit Hyperactivity Disorder and experienced Paranasal Sinus Hypersecretion *:
- female: 33.33 %
- male: 66.67 %
Age of people who have Attention Deficit Hyperactivity Disorder and experienced Paranasal Sinus Hypersecretion *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 40 %
- 20-29: 20 %
- 30-39: 40 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 0.0 %
Common co-existing conditions for these people *:
- Quit Smoking: 1 person, 16.67%
- Panic Disorder: 1 person, 16.67%
- Osteomyelitis (infection of bone): 1 person, 16.67%
- Insomnia (sleeplessness): 1 person, 16.67%
- Generalized Anxiety Disorder (excessive, uncontrollable, unexplained and often irrational worry): 1 person, 16.67%
- Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 1 person, 16.67%
Common drugs taken by these people *:
- Strattera: 4 people, 66.67%
- Zolpidem: 1 person, 16.67%
- Zaleplon: 1 person, 16.67%
- Vyvanse: 1 person, 16.67%
- Ultram: 1 person, 16.67%
- Humira: 1 person, 16.67%
- Clonazepam: 1 person, 16.67%
- Chantix: 1 person, 16.67%
Common symptoms for these people *:
- Drug Ineffective: 3 people, 50.00%
- Abnormal Behavior: 2 people, 33.33%
- Sneezing: 2 people, 33.33%
- Aggression: 2 people, 33.33%
- Pharyngolaryngeal Pain: 2 people, 33.33%
- Insomnia (sleeplessness): 1 person, 16.67%
- Anger: 1 person, 16.67%
- Breathing Difficulty: 1 person, 16.67%
- Cough: 1 person, 16.67%
- Drowsiness: 1 person, 16.67%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
- Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Treatments, associated drugs and conditions:
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (703 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (386 conditions)
How the study uses the data?
The study is based on Paranasal sinus hypersecretion and Attention deficit hyperactivity disorder, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Omeprazole and Imperforate Anus - now
- Bactrim and Protein Total Decreased - a second ago
- Hydroxyzine and Implant Site Abscess - a second ago
- Mirtazapine and Sodium Phosphates drug interaction - 4 seconds ago
- Acetazolamide and Pericardial Effusion - 10 seconds ago
- Tyvaso and Bile Duct Obstruction - 12 seconds ago
- Estazolam and Neuroleptic Malignant Syndrome - 14 seconds ago
- Ibuprofen and Metabolic Myopathy - 17 seconds ago
- Ocrevus and Belching - 21 seconds ago
- Enalapril Maleate and Iatrogenic Injury - 33 seconds ago